Annual CFF
$10.00 M
+$5.02 M+100.64%
31 December 2023
Summary:
Titan Pharmaceuticals annual cash flow from financing activities is currently $10.00 million, with the most recent change of +$5.02 million (+100.64%) on 31 December 2023. During the last 3 years, it has fallen by -$7.93 million (-44.24%). TTNP annual CFF is now -88.08% below its all-time high of $83.92 million, reached on 31 December 2000.TTNP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
N/A
30 June 2024
Summary:
Titan Pharmaceuticals quarterly cash flow from financing activities is not available.TTNP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
N/A
30 June 2024
Summary:
Titan Pharmaceuticals TTM cash flow from financing activities is not available.TTNP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTNP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +100.6% | - | - |
| 3 y3 years | -44.2% | - | - |
| 5 y5 years | -5.8% | - | - |
TTNP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -44.2% | +100.6% | ||||
| 5 y | 5 years | -44.2% | +100.6% | ||||
| alltime | all time | -88.1% | >+9999.0% |
Titan Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $10.00 M(+100.6%) | $406.00 K(-95.8%) | $10.00 M(+4.2%) |
| Sept 2023 | - | $9.59 M(>+9900.0%) | $9.59 M(+92.5%) |
| Dec 2022 | $4.98 M(-43.6%) | $0.00(0.0%) | $4.98 M(0.0%) |
| Sept 2022 | - | $0.00(-100.0%) | $4.98 M(0.0%) |
| June 2022 | - | $3000.00(-99.9%) | $4.98 M(+0.1%) |
| Mar 2022 | - | $4.98 M(>+9900.0%) | $4.98 M(-43.7%) |
| Dec 2021 | $8.84 M(-50.7%) | $0.00(0.0%) | $8.84 M(-40.1%) |
| Sept 2021 | - | $0.00(0.0%) | $14.75 M(-14.3%) |
| June 2021 | - | $0.00(-100.0%) | $17.22 M(-8.0%) |
| Mar 2021 | - | $8.84 M(+49.6%) | $18.72 M(+4.4%) |
| Dec 2020 | $17.93 M(+59.1%) | $5.91 M(+139.7%) | $17.93 M(-10.8%) |
| Sept 2020 | - | $2.47 M(+64.4%) | $20.10 M(+2.3%) |
| June 2020 | - | $1.50 M(-81.4%) | $19.65 M(+5.0%) |
| Mar 2020 | - | $8.06 M(-0.2%) | $18.72 M(+66.1%) |
| Dec 2019 | $11.27 M(+6.1%) | $8.08 M(+300.8%) | $11.27 M(+46.1%) |
| Sept 2019 | - | $2.02 M(+252.9%) | $7.71 M(-47.9%) |
| June 2019 | - | $571.00 K(-5.6%) | $14.80 M(+4.0%) |
| Mar 2019 | - | $605.00 K(-86.6%) | $14.22 M(+33.9%) |
| Dec 2018 | $10.62 M(+57.8%) | $4.52 M(-50.3%) | $10.62 M(+82.6%) |
| Sept 2018 | - | $9.10 M(>+9900.0%) | $5.82 M(+56.0%) |
| June 2018 | - | $0.00(-100.0%) | $3.73 M(0.0%) |
| Mar 2018 | - | -$3.00 M(+960.1%) | $3.73 M(-44.6%) |
| Dec 2017 | $6.73 M(>+9900.0%) | -$283.00 K(-104.0%) | $6.73 M(-4.0%) |
| Sept 2017 | - | $7.01 M(>+9900.0%) | $7.01 M(>+9900.0%) |
| Mar 2017 | - | $0.00(0.0%) | $27.00 K(0.0%) |
| Dec 2016 | $27.00 K(-292.9%) | $0.00(0.0%) | $27.00 K(0.0%) |
| Sept 2016 | - | $0.00(-100.0%) | $27.00 K(0.0%) |
| June 2016 | - | $27.00 K(>+9900.0%) | $27.00 K(-292.9%) |
| Dec 2015 | -$14.00 K(-100.1%) | $0.00(0.0%) | -$14.00 K(-100.1%) |
| Sept 2015 | - | $0.00(0.0%) | $9.58 M(0.0%) |
| June 2015 | - | $0.00(-100.0%) | $9.58 M(+0.4%) |
| Mar 2015 | - | -$14.00 K(-100.1%) | $9.54 M(-0.1%) |
| Dec 2014 | $9.55 M(+150.6%) | $9.59 M(>+9900.0%) | $9.55 M(+95.5%) |
| Sept 2014 | - | $0.00(-100.0%) | $4.89 M(0.0%) |
| June 2014 | - | -$37.00 K(<-9900.0%) | $4.89 M(+101.6%) |
| Mar 2014 | - | $0.00(-100.0%) | $2.42 M(-36.4%) |
| Dec 2013 | $3.81 M(-68.3%) | $4.92 M(>+9900.0%) | $3.81 M(+48.7%) |
| Sept 2013 | - | $0.00(-100.0%) | $2.56 M(-57.5%) |
| June 2013 | - | -$2.50 M(-280.1%) | $6.03 M(-55.2%) |
| Mar 2013 | - | $1.39 M(-62.2%) | $13.45 M(+11.9%) |
| Dec 2012 | $12.02 M(-29.0%) | $3.68 M(+6.0%) | $12.02 M(-9.9%) |
| Sept 2012 | - | $3.47 M(-29.5%) | $13.34 M(+35.1%) |
| June 2012 | - | $4.92 M(<-9900.0%) | $9.88 M(-42.5%) |
| Mar 2012 | - | -$44.00 K(-100.9%) | $17.16 M(+1.3%) |
| Dec 2011 | $16.94 M(+271.0%) | $5.00 M(>+9900.0%) | $16.94 M(+45.1%) |
| Sept 2011 | - | $0.00(-100.0%) | $11.67 M(-29.3%) |
| June 2011 | - | $12.21 M(-4588.2%) | $16.50 M(+284.4%) |
| Mar 2011 | - | -$272.00 K(+3.4%) | $4.29 M(-6.0%) |
| Dec 2010 | $4.57 M(+13.2%) | -$263.00 K(-105.4%) | $4.57 M(-45.6%) |
| Sept 2010 | - | $4.83 M(>+9900.0%) | $8.38 M(+107.9%) |
| June 2010 | - | $0.00(0.0%) | $4.03 M(0.0%) |
| Mar 2010 | - | $0.00(-100.0%) | $4.03 M(0.0%) |
| Dec 2009 | $4.03 M | $3.56 M(+647.3%) | $4.03 M(+747.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2009 | - | $476.00 K(>+9900.0%) | $476.00 K(>+9900.0%) |
| June 2009 | - | $0.00(0.0%) | $0.00(-100.0%) |
| Sept 2008 | - | $0.00(0.0%) | $20.85 M(-0.1%) |
| June 2008 | - | $0.00(-100.0%) | $20.88 M(-32.8%) |
| Mar 2008 | - | -$26.00 K(-100.1%) | $31.09 M(-0.4%) |
| Dec 2007 | $31.21 M(+215.6%) | $20.87 M(>+9900.0%) | $31.21 M(+198.0%) |
| Sept 2007 | - | $31.00 K(-99.7%) | $10.47 M(-0.1%) |
| June 2007 | - | $10.21 M(>+9900.0%) | $10.49 M(+3857.0%) |
| Mar 2007 | - | $96.00 K(-30.4%) | $265.00 K(-97.3%) |
| Dec 2006 | $9.89 M(+143.2%) | $138.00 K(+206.7%) | $9.89 M(-27.9%) |
| Sept 2006 | - | $45.00 K(-421.4%) | $13.72 M(+0.2%) |
| June 2006 | - | -$14.00 K(-100.1%) | $13.69 M(-0.5%) |
| Mar 2006 | - | $9.72 M(+144.9%) | $13.76 M(+238.4%) |
| Dec 2005 | $4.07 M(-72.1%) | $3.97 M(>+9900.0%) | $4.07 M(+3736.8%) |
| Sept 2005 | - | $16.00 K(-72.4%) | $106.00 K(-27.4%) |
| June 2005 | - | $58.00 K(+141.7%) | $146.00 K(+31.5%) |
| Mar 2005 | - | $24.00 K(+200.0%) | $111.00 K(-99.2%) |
| Dec 2004 | $14.57 M(>+9900.0%) | $8000.00(-85.7%) | $14.57 M(-0.4%) |
| Sept 2004 | - | $56.00 K(+143.5%) | $14.62 M(+0.1%) |
| June 2004 | - | $23.00 K(-99.8%) | $14.61 M(+0.1%) |
| Mar 2004 | - | $14.48 M(>+9900.0%) | $14.59 M(>+9900.0%) |
| Dec 2003 | $113.00 K(-2925.0%) | $66.00 K(+78.4%) | $113.00 K(+169.0%) |
| Sept 2003 | - | $37.00 K(+270.0%) | $42.00 K(+950.0%) |
| June 2003 | - | $10.00 K(>+9900.0%) | $4000.00(-180.0%) |
| Mar 2003 | - | $0.00(-100.0%) | -$5000.00(+25.0%) |
| Dec 2002 | -$4000.00(-100.4%) | -$5000.00(+400.0%) | -$4000.00(-105.6%) |
| Sept 2002 | - | -$1000.00(-200.0%) | $72.00 K(-2.7%) |
| June 2002 | - | $1000.00(0.0%) | $74.00 K(-75.3%) |
| Mar 2002 | - | $1000.00(-98.6%) | $300.00 K(-67.4%) |
| Dec 2001 | $921.00 K(-98.9%) | $71.00 K(+7000.0%) | $921.00 K(-97.8%) |
| Sept 2001 | - | $1000.00(-99.6%) | $41.92 M(-1.2%) |
| June 2001 | - | $227.00 K(-63.5%) | $42.44 M(-1.0%) |
| Mar 2001 | - | $622.00 K(-98.5%) | $42.87 M(-48.9%) |
| Dec 2000 | $83.92 M(+83.2%) | $41.07 M(+7737.8%) | $83.92 M(+1.5%) |
| Sept 2000 | - | $524.00 K(-20.1%) | $82.64 M(+0.4%) |
| June 2000 | - | $656.00 K(-98.4%) | $82.32 M(+0.8%) |
| Mar 2000 | - | $41.66 M(+4.7%) | $81.67 M(+78.3%) |
| Dec 1999 | $45.80 M(>+9900.0%) | $39.80 M(>+9900.0%) | $45.80 M(+663.3%) |
| Sept 1999 | - | $200.00 K(>+9900.0%) | $6.00 M(+3.4%) |
| June 1999 | - | $0.00(-100.0%) | $5.80 M(-1.7%) |
| Mar 1999 | - | $5.80 M(>+9900.0%) | $5.90 M(+2850.0%) |
| Dec 1998 | $200.00 K(-94.6%) | $0.00(0.0%) | $200.00 K(-96.2%) |
| Sept 1998 | - | $0.00(-100.0%) | $5.30 M(0.0%) |
| June 1998 | - | $100.00 K(0.0%) | $5.30 M(+32.5%) |
| Mar 1998 | - | $100.00 K(-98.0%) | $4.00 M(+8.1%) |
| Dec 1997 | $3.70 M(-84.9%) | $5.10 M(>+9900.0%) | $3.70 M(-384.6%) |
| Sept 1997 | - | $0.00(-100.0%) | -$1.30 M(-110.6%) |
| June 1997 | - | -$1.20 M(+500.0%) | $12.30 M(-9.6%) |
| Mar 1997 | - | -$200.00 K(-300.0%) | $13.60 M(-44.5%) |
| Dec 1996 | $24.50 M(+195.2%) | $100.00 K(-99.3%) | $24.50 M(+0.4%) |
| Sept 1996 | - | $13.60 M(>+9900.0%) | $24.40 M(+125.9%) |
| June 1996 | - | $100.00 K(-99.1%) | $10.80 M(+0.9%) |
| Mar 1996 | - | $10.70 M | $10.70 M |
| Dec 1995 | $8.30 M | - | - |
FAQ
- What is Titan Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Titan Pharmaceuticals?
- What is Titan Pharmaceuticals annual CFF year-on-year change?
- What is the all time high quarterly CFF for Titan Pharmaceuticals?
- What is the all time high TTM CFF for Titan Pharmaceuticals?
What is Titan Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of TTNP is $10.00 M
What is the all time high annual CFF for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high annual cash flow from financing activities is $83.92 M
What is Titan Pharmaceuticals annual CFF year-on-year change?
Over the past year, TTNP annual cash flow from financing activities has changed by +$5.02 M (+100.64%)
What is the all time high quarterly CFF for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high quarterly cash flow from financing activities is $41.66 M
What is the all time high TTM CFF for Titan Pharmaceuticals?
Titan Pharmaceuticals all-time high TTM cash flow from financing activities is $83.92 M